2022
Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects
Peters S, Paz-Ares L, Herbst RS, Reck M. Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects. Journal For ImmunoTherapy Of Cancer 2022, 10: e004863. PMID: 35858709, PMCID: PMC9305809, DOI: 10.1136/jitc-2022-004863.Peer-Reviewed Original ResearchConceptsImmunosuppressive tumor microenvironmentCheckpoint inhibitorsTAM receptorsImmune responseTumor microenvironmentOverall survivalLung cancerStandard first-line therapyLong-term clinical responseCell death protein 1Immunostimulatory tumor microenvironmentImmune checkpoint inhibitorsInhibitor-based regimensFirst-line therapyAntitumor immune responseDeath protein 1Cell lung cancerPatients' overall survivalStrong biological rationaleNew treatment approachesLong-term survivalActivation of Tyro3Majority of casesCPI therapyAdvanced NSCLC
2017
Immuno-thermal ablations – boosting the anticancer immune response
Slovak R, Ludwig JM, Gettinger SN, Herbst RS, Kim HS. Immuno-thermal ablations – boosting the anticancer immune response. Journal For ImmunoTherapy Of Cancer 2017, 5: 78. PMID: 29037259, PMCID: PMC5644150, DOI: 10.1186/s40425-017-0284-8.Peer-Reviewed Original ResearchConceptsImmune responseImmune effectsRobust antitumor responseAnticancer immune responseImmune modulating drugsUse of immunomodulationSystemic antitumor activityCheckpoint blockadeAntitumor responseAblative therapyCombination therapyRadiofrequency ablationAblative techniquesModulating drugsAnimal modelsAntitumor activityThermal ablationTherapeutic appealImmunomodulationTherapyAblationResponseMonotherapyImmunomodulatorsCryoablationInterplay between immune infiltration and tumor progression and survival in non-small cell lung cancer: An analysis of institutional and public data.
Jalali A, Wang J, Lee W, Zhang J, Wu C, Gibbons D, Tang X, Kalhor N, Izzo J, Behrens C, Fossella F, Tsao A, Lee J, Swisher S, Heymach J, Futreal A, Wistuba I, Herbst R, Papadimitrakopoulou V, Zhang J. Interplay between immune infiltration and tumor progression and survival in non-small cell lung cancer: An analysis of institutional and public data. Journal Of Clinical Oncology 2017, 35: 8538-8538. DOI: 10.1200/jco.2017.35.15_suppl.8538.Peer-Reviewed Original ResearchNon-small cell lung cancerImmune infiltration scoreTumor immune infiltrationCell lung cancerImmune infiltrationLung cancerImmune responseAdvanced non-small cell lung cancerStage I/II diseaseTumor progressionStage I/IIStage III/IVInfiltration of tumorsInflammatory cell countsHigher median survivalLung Cancer ProjectPrimary tumor specimensLung adenocarcinoma samplesTypes of cancerMeans of CD3Tumor coreEstimate packageMedian survivalNSCLC patientsClinical outcomes